![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The financing aims to support the continued development of CIN-102 (deudomperidone) for the treatment of chronic gastroparesis, including preparation for registrational trials.
Lead Product(s): Deudomperidone
Therapeutic Area: Gastroenterology Product Name: CIN-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CinRx Pharma
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 16, 2024
Details:
The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.
Lead Product(s): Deudomperidone
Therapeutic Area: Gastroenterology Product Name: CIN-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CinRx Pharma & Perceptive Advisors
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 27, 2023
Details:
CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.
Lead Product(s): Deudomperidone
Therapeutic Area: Gastroenterology Product Name: CIN-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023